A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Phase 3
1,035
about 2.2 years
18+
60 sites in AL, AZ, CA +22
What this study is about
Researchers are testing eloralintide compared to a placebo for weight loss in people with obesity or overweight who also have type 2 diabetes. The trial will last about 75 weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Eloralintide
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Percent Change from Baseline in Body Weight
Secondary: Change from Baseline in Body Mass Index (BMI), Change from Baseline in Control of Eating Questionnaire (CoEQ) Score, Change from Baseline in EQ-5D-5L Score, Change from Baseline in Estimated Glomerular Filtration Rate (eGFR), Change from Baseline in Hemoglobin A1c (HbA1c), Change from Baseline in Short Form-36 (SF-36 v2) Score, Change from Baseline in Systolic Blood Pressure, Change from Baseline in Waist Circumference
Endocrinology